BACKGROUND:Endovascular therapy is increasingly used after the administration of intravenous tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic stroke, but whether a combined approach is more effective than intravenous t-PA alone is uncertain. METHODS: We randomly assigned eligible patients who had received intravenous t-PA within 3 hours after symptom onset to receive additional endovascular therapy or intravenous t-PA alone, in a 2:1 ratio. The primary outcome measure was a modified Rankin scale score of 2 or less (indicating functional independence) at 90 days (scores range from 0 to 6, with higher scores indicating greater disability). RESULTS: The study was stopped early because of futility after 656 participants had undergone randomization (434 patients to endovascular therapy and 222 to intravenous t-PA alone). The proportion of participants with a modified Rankin score of 2 or less at 90 days did not differ significantly according to treatment (40.8% with endovascular therapy and 38.7% with intravenous t-PA; absolute adjusted difference, 1.5 percentage points; 95% confidence interval [CI], -6.1 to 9.1, with adjustment for the National Institutes of Health Stroke Scale [NIHSS] score [8-19, indicating moderately severe stroke, or ≥20, indicating severe stroke]), nor were there significant differences for the predefined subgroups of patients with an NIHSS score of 20 or higher (6.8 percentage points; 95% CI, -4.4 to 18.1) and those with a score of 19 or lower (-1.0 percentage point; 95% CI, -10.8 to 8.8). Findings in the endovascular-therapy and intravenous t-PA groups were similar for mortality at 90 days (19.1% and 21.6%, respectively; P=0.52) and the proportion of patients with symptomatic intracerebral hemorrhage within 30 hours after initiation of t-PA (6.2% and 5.9%, respectively; P=0.83). CONCLUSIONS: The trial showed similar safety outcomes and no significant difference in functional independence with endovascular therapy after intravenous t-PA, as compared with intravenous t-PA alone. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00359424.).
RCT Entities:
BACKGROUND: Endovascular therapy is increasingly used after the administration of intravenous tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic stroke, but whether a combined approach is more effective than intravenous t-PA alone is uncertain. METHODS: We randomly assigned eligible patients who had received intravenous t-PA within 3 hours after symptom onset to receive additional endovascular therapy or intravenous t-PA alone, in a 2:1 ratio. The primary outcome measure was a modified Rankin scale score of 2 or less (indicating functional independence) at 90 days (scores range from 0 to 6, with higher scores indicating greater disability). RESULTS: The study was stopped early because of futility after 656 participants had undergone randomization (434 patients to endovascular therapy and 222 to intravenous t-PA alone). The proportion of participants with a modified Rankin score of 2 or less at 90 days did not differ significantly according to treatment (40.8% with endovascular therapy and 38.7% with intravenous t-PA; absolute adjusted difference, 1.5 percentage points; 95% confidence interval [CI], -6.1 to 9.1, with adjustment for the National Institutes of Health Stroke Scale [NIHSS] score [8-19, indicating moderately severe stroke, or ≥20, indicating severe stroke]), nor were there significant differences for the predefined subgroups of patients with an NIHSS score of 20 or higher (6.8 percentage points; 95% CI, -4.4 to 18.1) and those with a score of 19 or lower (-1.0 percentage point; 95% CI, -10.8 to 8.8). Findings in the endovascular-therapy and intravenous t-PA groups were similar for mortality at 90 days (19.1% and 21.6%, respectively; P=0.52) and the proportion of patients with symptomatic intracerebral hemorrhage within 30 hours after initiation of t-PA (6.2% and 5.9%, respectively; P=0.83). CONCLUSIONS: The trial showed similar safety outcomes and no significant difference in functional independence with endovascular therapy after intravenous t-PA, as compared with intravenous t-PA alone. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00359424.).
Authors: Kennedy R Lees; Erich Bluhmki; Rüdiger von Kummer; Thomas G Brott; Danilo Toni; James C Grotta; Gregory W Albers; Markku Kaste; John R Marler; Scott A Hamilton; Barbara C Tilley; Stephen M Davis; Geoffrey A Donnan; Werner Hacke; Kathryn Allen; Jochen Mau; Dieter Meier; Gregory del Zoppo; D A De Silva; K S Butcher; M W Parsons; P A Barber; C Levi; C Bladin; G Byrnes Journal: Lancet Date: 2010-05-15 Impact factor: 79.321
Authors: T A Tomsick; P Khatri; T Jovin; B Demaerschalk; T Malisch; A Demchuk; M D Hill; E Jauch; J Spilker; J P Broderick Journal: Neurology Date: 2010-03-30 Impact factor: 9.910
Authors: Felipe de Los Ríos la Rosa; Jane Khoury; Brett M Kissela; Matthew L Flaherty; Kathleen Alwell; Charles J Moomaw; Pooja Khatri; Opeolu Adeoye; Daniel Woo; Simona Ferioli; Dawn O Kleindorfer Journal: Stroke Date: 2012-03-22 Impact factor: 7.914
Authors: Philip M Meyers; H Christian Schumacher; E Sander Connolly; Eric J Heyer; William A Gray; Randall T Higashida Journal: Circulation Date: 2011-06-07 Impact factor: 29.690
Authors: Alex Abou-Chebl; Ridwan Lin; Muhammad Shazam Hussain; Tudor G Jovin; Elad I Levy; David S Liebeskind; Albert J Yoo; Daniel P Hsu; Marilyn M Rymer; Ashis H Tayal; Osama O Zaidat; Sabareesh K Natarajan; Raul G Nogueira; Ashish Nanda; Melissa Tian; Qing Hao; Junaid S Kalia; Thanh N Nguyen; Michael Chen; Rishi Gupta Journal: Stroke Date: 2010-04-15 Impact factor: 7.914
Authors: Raul G Nogueira; Helmi L Lutsep; Rishi Gupta; Tudor G Jovin; Gregory W Albers; Gary A Walker; David S Liebeskind; Wade S Smith Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Jeffrey L Saver; Reza Jahan; Elad I Levy; Tudor G Jovin; Blaise Baxter; Raul G Nogueira; Wayne Clark; Ronald Budzik; Osama O Zaidat Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Christian H Riedel; Philip Zimmermann; Ulf Jensen-Kondering; Robert Stingele; Günther Deuschl; Olav Jansen Journal: Stroke Date: 2011-04-07 Impact factor: 7.914
Authors: Alexandra Graves; David Case; Rajan Gupta; Angel Pulido; Kimberly Rapp; Jennifer R Simpson; Doreen Smith; William J Jones Journal: Semin Intervent Radiol Date: 2013-09 Impact factor: 1.513
Authors: Mayank Goyal; Mohammed A Almekhlafi; Liqiong Fan; Bijoy K Menon; Andrew M Demchuk; Sharon D Yeatts; Michael D Hill; Thomas Tomsick; Pooja Khatri; Osama O Zaidat; Edward C Jauch; Muneer Eesa; Tudor G Jovin; Joseph P Broderick Journal: Circulation Date: 2014-05-09 Impact factor: 29.690